Evaluation of 8% Capsaicin Patches in Chemotherapy-Induced Peripheral Neuropathy: A Retrospective Study in a Comprehensive Cancer Center

SIMPLE SUMMARY: Chemotherapy-induced peripheral neuropathy (CIPN) is often painful, arising during or after the end of oncological treatments. The high-concentration capsaicin patch (HCCP) is recommended in second line for its treatment but based on low-powered studies. The objective of this retrospective real-world-data study was to evaluate efficacy and tolerability of HCCP applications in CIPN. Our study demonstrated an important or complete pain relief for 33.2% of the applications, corresponding to 43.9% patients. We found a significative difference in efficacy depending on the responsible chemotherapy. The efficacy was significatively different depending on the analgesic treatment line for HCCP. The efficacy of HCCP was significatively higher starting the third application. HCCPs were mainly responsible for local adverse events. HCCP applications in painful CIPN induce important pain relief with a global satisfying tolerability. ABSTRACT: Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) is often painful and can arise during or after the end of oncological treatments. They are mostly induced by platinum salts, taxanes, and immunotherapies. Their incidence is estimated between 19 and 85%. They can require a chemotherapy dose reduction or early termination. The European Society for Medical Oncology (ESMO) recommends high-concentration capsaicin patch (HCCP) in second line for the treatment of painful CIPN. This treatment induces a significative pain relief but only shown by low-powered studies. The objective of this study was to evaluate efficacy and tolerability of HCCP applications in CIPN. Methods: This monocentric observational retrospective real-world-data study of the CERCAN cohort took place in the Western Cancer Institute’s Anaesthesiology and Pain Department at Angers, France. Independent pain physicians completed the CGIC (Clinician Global Impression of Change) for each patient who benefited from HCCP applications for painful CIPN starting from 1 January 2014 to 22 December 2021, based on the collected data after every patch application. Results: A total of 57 patients (80.7% women) was treated with HCCP for painful CIPN, and 184 applications were realized, consisting of 296 sessions. CGIC found an important or complete pain relief for 61 applications (33.2%, corresponding to 43.9% patients). We found less efficacy for platinum-salts-induced CIPN compared to others (p = 0.0238). The efficacy was significatively higher for repeated applications when HCCP was used in second line compared to third line (p = 0.018). The efficacy of HCCP was significatively higher starting the third application (p = 0.0334). HCCPs were mainly responsible for local adverse events found in 66.6% patients (65.1% burning or painful sensation, 21.1% erythema). Conclusion: HCCP applications in painful CIPN induce an important pain relief with a global satisfying tolerability.